This study describes the rates of and factors associated with discontinuation of GLP-1 RAs and dual gastric inhibitory polypeptide receptor–GLP-1 RAs labeled for both type 2 diabetes and obesity (liraglutide, semaglutide, and tirzepatide) in adults with or without type 2 diabetes. The gene discussed is GLP1R; the disease is obesity disorder.